Pharmaceutical company
Appears in 14 stories · Last updated Nov 10, 2026
Prior collaborator
Every medicine argenx sells today reaches patients by infusion or injection. On Nov. 9, 2026, the Dutch immunology company agreed to pay $550 million in cash for a Santa Cruz company whose chemistry is built to make pills instead.
Updated Yesterday
Manufacturer of the Ervebo vaccine
Congo's frontline health workers are still receiving the only Ebola vaccine available at scale, though it was designed for a different virus. The BRAVO study, which began September 19, is following 20,000 health workers in Ituri and North Kivu to see whether Ervebo protects them against Bundibugyo.
Updated 6 days ago
Co-develops sac-TMT with Kelun-Biotech; had not launched a global Phase III trial of the conjugate in first-line NSCLC as of late October 2026
Pairing an antibody-drug conjugate with pembrolizumab kept advanced lung cancer from worsening for a median of 15 months, nearly three times as long as the standard pembrolizumab-plus-chemotherapy regimen. The Phase III OptiTROP-Lung06 results were presented on October 25 at the ESMO congress in Madrid and published the same day in the New England Journal of Medicine.
Updated Oct 27
Sponsor of remigromig development
Jefferies cut its risk-adjusted peak sales estimate for remigromig by 60%, to $300 million. The change followed Merck's presentation of full one-year BRUNELLO results at the American Academy of Ophthalmology meeting in October. In the 984-patient trial, the drug matched ranibizumab on vision but produced smaller gains and higher rates of proliferative diabetic retinopathy.
Updated Oct 26
Supplies pembrolizumab (Keytruda) for the olomorasib combination trials
KRAS G12C-mutant non-small cell lung cancer has no approved first-line targeted therapy. Standard care is immunotherapy with or without chemotherapy, and most patients never reach second-line treatment, so the first choice carries a lot of weight.
Co-developer; Phase 3 melanoma trial met primary endpoint
Cancer vaccines have promised to train the immune system against tumors for decades. None has delivered a durable, replicable benefit until now.
Updated Oct 25
As of October 2026: Maker of Capvaxive, a comparator in OPUS-1
Vaxcyte said Monday its experimental pneumococcal vaccine met every primary goal in the first of three late-stage trials. VAX-31, which targets 31 strains of the bacteria behind pneumonia and meningitis, matched Pfizer's Prevnar 20 and Merck's Capvaxive on nearly all shared strains, beat both on three strains only it covers, and sent shares up roughly 50% to push the company's market value past $12 billion.
Updated Oct 7
As of September 2026: Co-developer of ifinatamab deruxtecan
Merck and Daiichi Sankyo withdrew their US application for ifinatamab deruxtecan, an experimental antibody-drug conjugate for extensive-stage small cell lung cancer, an aggressive disease that has resisted most new treatments. The FDA had told the companies their Phase 2 data were not enough to support accelerated approval, and the bid was pulled on September 25.
Updated Sep 29
As of July 2026: Developer and seller of Lipfendra
For a decade, the most powerful cholesterol drugs came only as shots. On July 16, 2026, the FDA approved Merck's Lipfendra, a once-daily pill that cut LDL cholesterol about as much as those injections did.
Updated Jul 16
As of June 2026: Maker of both belzutifan (Welireg) and pembrolizumab (Keytruda)
Surgery removes the tumor. For many high-risk kidney cancer patients, it doesn't end the disease. On June 12, 2026, the U.S. Food and Drug Administration (FDA) approved pairing belzutifan with the immunotherapy pembrolizumab to keep these patients cancer-free for longer after their kidney is removed.
Updated Jun 12
As of May 2026: Advancing enlicitide decanoate toward FDA filing after positive Phase 3 results
For two decades, lowering LDL cholesterol meant statins—daily pills that work for most but leave roughly one in five patients with muscle pain or liver enzyme changes severe enough to quit. On May 1, researchers from the University of Barcelona and Oregon Health & Science University reported that engineered DNA reduced LDL by nearly 50 percent in mice. A single injection of this engineered DNA molecule silences the gene controlling how the liver clears LDL.
Updated May 31
As of May 2026: Acquirer — executing multiyear pipeline-rebuilding strategy
Keytruda, the world's best-selling drug, generated $31.7 billion for Merck in 2025 — roughly 40% of the company's total revenue. Its key U.S. patents expire in 2028, and when they do, cheaper copies will enter the market and that revenue will begin to evaporate. Merck has now spent over $25 billion on three acquisitions in nine months to build the portfolio that will need to replace it.
Updated May 30
As of May 2026: Active acquirer, refinancing biotech purchases in debt markets
Merck borrowed billions in the investment-grade bond market on Monday. The cash refinances its $6.7 billion all-cash purchase of Terns Pharmaceuticals, a small California biotech the company closed on two weeks ago.
Updated May 18
As of May 2026: Expanding infectious disease portfolio through $9.2B Cidara acquisition
Sanofi dropped $2.2 billion on December 24, 2025 to acquire Dynavax, a California biotech with a two-dose hepatitis B vaccine and a shingles vaccine in development. The 39% premium signals desperation in a market projected to hit $37.2 billion by 2033, driven by aging populations; the deal is expected to close in Q1 2026 pending Hart-Scott-Rodino antitrust clearance.[1] By 2050, 2.1 billion people will be over 60, triple the population over 80.
Updated May 16
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
